ClosedPublished 11 Sep 2025

Bausch Health Companies Inc. /
DURECT Corporation

Bausch Health adds DURECT to its hepatology pipeline

Buy side: Bausch Health Companies Inc.
Buy sideBausch Health Companies Inc.
Target: DURECT Corporation
TargetDURECT Corporation
Bausch Health Companies Inc. · 11 Sep 2025Source
Buy side: Bausch Health Companies Inc.
Buy sideBausch Health Companies Inc.
Target: DURECT Corporation
TargetDURECT Corporation
01 / BuyerBausch Health Companies Inc.
02 / TargetDURECT Corporation
Source for the buyer and target: Bausch Health Companies Inc.

For the buyer and target.

“LAVAL, QC, and CUPERTINO, CA, September 11, 2025 – Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) (“Bausch Health”), a global, diversified pharmaceutical company, today announced the successful completion of its previously announced tender offer to acquire DURECT Corporation (“DURECT”).”

Published 11 Sep 2025

Open the source
01

What happened

Bausch Health Companies Inc. completed its acquisition of DURECT Corporation, adding larsucosterol to its hepatology pipeline. [01]

The deal included an upfront cash payment of approximately $63 million at closing, with potential additional net sales milestone payments of up to $350 million in the aggregate. [01]

02

The source

Everything on this page comes from the source below, quoted word for word.

01
Source · Bausch Health Companies Inc.

Bausch Health adds DURECT to its hepatology pipeline

This document is the source for the companies, stage, figure and people on this page.

Open the source
03

Timeline

Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by Bausch Health Companies Inc.

    The source this page is built from.

    Open the source

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Get ProAlready a member? Sign in

Pro is open to everyone.